Nano-X Imaging Ltd is a medical technology company focused on transforming the field of medical imaging by developing innovative imaging solutions
Their flagship product is a digital X-ray system that aims to provide cost-effective, accessible, and efficient imaging services, particularly in underserved markets. The company combines advanced technology and artificial intelligence to enhance diagnostic capabilities and improve patient outcomes. By leveraging its cutting-edge platform, Nano-X is dedicated to democratizing healthcare through the deployment of sophisticated imaging equipment, ultimately making diagnostic tools more widely available for healthcare providers and patients alike.
Over the last few trading sessions we have seen the power of the Nvidia (NVDA) halo. The halo is the coming to us in the form of investments NVDA has made in some smaller companies that are partners and or customers.
Bitcoin smashes $100K! Discover what this milestone means for crypto and risk assets, plus our Top 5 stock picks for the day analyzed through catalysts, sentiment, fundamentals, and technicals.
Nano-X Imaging Ltd. (NASDAQNNOX) shares are trading higher Thursday after the company announced FDA clearance for its Nano.ARC stationary x-ray system.
PETACH TIKVA, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Nanox.ARC, a stationary X-ray system intended to produce tomographic images for general use including human musculoskeletal system, pulmonary, intra-abdominal, and paranasal sinus indications, adjunctive to conventional radiography, on adult patients.
Nvidia's purchase of 7.72 million shares of Applied Digital boosted the company's revenue and earnings. Applied Digital plans to expand its data centers and AI cloud infrastructure.
PETACH TIKVA, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended September 30, 2024, before market open on Thursday, November 21, 2024. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.
PETACH TIKVA, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that Company management will participate in an investor conference in the month of September 2024:
PETACH TIKVA, Israel, Aug. 06, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended June 30, 2024, before market open on Tuesday, August 20, 2024. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.
In a study conducted by Brigham & Women’s Hospital, Nanox.AI-Based Analysis helps Reveal Coronary Artery Calcium in over 50% of IMID Patients; Lead author Brittany Weber, MD, PhD, declared as ‘Young Investigator Awards’ Winner
